Purchase Order 75N95023P00627
Award Date
8/24/23
Potential Completion Date
3/31/24
Potential Value
$72K
Funding Federal Agency
National Center for Advancing Translational Sciences
Contracting Federal Agency
National Institute on Drug Abuse
Awardee
Xenobiotic Laboratories Inc.
Ultimate Awardee
Not listed
Set-Aside Type
No Set-Aside Used
Federal Contract Vehicle
Extent Competed
Competed under SAP
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Plainsboro Township, NJ 08536, USA
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
The Department of Health and Human Services' National Institutes of Health National Center for Advancing Translational Sciences awarded a $134,500 firm fixed price purchase order to Xenobiotic Laboratories Inc. Biotesting Division for assessment of inhibition activity and substrate potential of two test articles for major human drug transporters. The solicitation requested the prime contractor evaluate Mitragynine and its metabolite 7-hydroxymitragynine to support drug development, using study...
Xenobiotic Laboratories Inc. was awarded a firm fixed price delivery order against the Analytical Services Center for Medications Development Program indefinite delivery/indefinite quantity contract vehicle. This two year task order, valued at $0 with a period of performance from September 2020 through September 2022, calls for Xenobiotic Laboratories' Biotesting Division to provide analytical services in support of the National Institute on Drug Abuse's medication development programs. No...
Xenobiotic Laboratories Inc. was awarded a firm fixed price delivery order against the Analytical Services Center for Medications Development Program for analytical services. The delivery order, valued at $0.00 with a period of performance from September 25, 2019 through May 23, 2022, was issued by the National Institute on Drug Abuse, part of the Department of Health and Human Services National Institutes of Health. Under the delivery order, Xenobiotic Laboratories Inc.'s Biotesting Division...
Xenobiotic Laboratories Inc. was awarded a firm fixed price delivery order against the Analytical Services Center for Medications Development Program for analytical services. The one year, $0.00 potential value task order was awarded by the National Institute on Drug Abuse within the Department of Health and Human Services to support the Center's work developing medications. Performance will take place in Plainsboro Township, New Jersey by Xenobiotic's Biotesting Division. No set aside...
This task order was awarded under the Analytical Services Center for Medications Development Program indefinite-delivery/indefinite-quantity contract by the National Institutes of Health's National Institute on Drug Abuse to Xenobiotic Laboratories Inc.'s Biotesting Division. The $0 task order provides administrative support services for the Analytical Services Center for Medications Development Program, which aims to develop new medications for substance use disorders. Performance will take...
This is a delivery order contract awarded by the National Center for Advancing Translational Sciences (NCATS), a component of the U.S. Department of Health and Human Services. The contract, valued at $2,373,515.00, is for non-clinical safety evaluations of mitragynine to support its future development as an oral analgesic (pain relief) therapy. The prime contractor is the IIT Research Institute (IITRI), a non-profit contract research organization and division of the Illinois Institute of...
The Department of Health and Human Services National Institutes of Health National Institute of Neurological Disorders and Stroke awarded a $6,338 firm fixed price purchase order to Cyprotex US LLC for ADME-TOX screening services in support of preliminary safety assessment of a new lead candidate for the agency's HER3 receptor project. Work will be performed by Cyprotex US LLC Division in Watertown, Massachusetts over a one year period concluding on August 30, 2024. The award was made using...
This is a firm-fixed-price purchase order awarded by the National Institute on Drug Abuse (NIDA), a civilian agency under the Department of Health and Human Services, to Cyprotex US LLC, a foreign-owned for-profit contract research organization. The $109,392.00 contract is for compound testing services, including plasma protein binding studies, PXR and AhR activation studies, and CYP inhibition assays on various small molecule compounds. This work supports NIDA's mission to seek fundamental...
This is a federal contract awarded by the National Center for Advancing Translational Sciences (NCATS), a civilian agency within the Department of Health and Human Services (HHS), to Cyprotex US LLC, a leading contract research organization specializing in predictive toxicology and ADME (absorption, distribution, metabolism, and excretion) research. The $18,024.00 firm fixed-price purchase order contract is for the testing of two compounds against key ADME and DMPK (drug metabolism and...
This firm fixed price purchase order awards $56,313 to Cyprotex US LLC to provide in vitro absorption, distribution, metabolism, excretion, and toxicity (ADMET) characterization services in support of the Department of Health and Human Services (HHS), National Institutes of Health (NIH), National Cancer Institute's (NCI) Developmental Therapeutics Program (DTP). The contractor will evaluate two small molecule drug candidates total across 11 specified in vitro ADMET assays, including metabolic...